Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 12/20 | 0.61 |
| ▸ | ESR1 | P03372 | 11/20 | 0.61 |
| ▸ | NQO2 | P16083 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | BCR | P11274 | 1/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312189 | 0.87 | ESR1 (0.67) | ESR2ESR1NQO2HSD17B1HSD17B2 | |
| SCHEMBL8196720 | 0.84 | NQO2 (0.67) | ESR2ESR1NQO2HSD17B1HSD17B2 | |
| SCHEMBL14506125 | 0.82 | ESR2 (0.83) | ESR2ESR1ABL1ABCB1BCR | |
| SCHEMBL3107306 | 0.82 | ESR2 (0.83) | ESR2ESR1ABL1ABCB1BCR | |
| SCHEMBL11978649 | 0.81 | ESR2 (0.80) | ESR2ESR1ABL1ABCB1BCR | |
| SCHEMBL29587268 | 0.81 | ESR2 (0.80) | ESR2ESR1ABL1ABCB1BCR | |
| SCHEMBL27845544 | 0.80 | ALOX5 (0.62) | ESR2ESR1NQO2ABL1ABCB1 | |
| SCHEMBL6467361 | 0.79 | NQO2 (0.59) | ESR2ESR1NQO2HSD17B1HSD17B2 | |
| SCHEMBL589557 | 0.79 | NQO2 (0.59) | ESR2ESR1NQO2HSD17B1HSD17B2 | |
| SCHEMBL13302145 | 0.78 | ESR2 (0.51) | ESR2ESR1NQO2ABL1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227313-B2 | Process for making benzoxazines | CYTEC INDUSTRIES INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180127387-A1 | PROCESS FOR MAKING BENZOXAZINES | CYTEC INDUSTRIES INC. (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127387-A1 | PROCESS FOR MAKING BENZOXAZINES | XDH, AFF1, TYR | ESR2 2829/4885ESR1 730/4885NQO2 1756/4885 |
| US-10227313-B2 | Process for making benzoxazines | XDH, AFF1, TYR | ESR2 2829/4885ESR1 730/4885NQO2 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.